News Column

Neurovive Pharmaceutical Reports Supplementary Subscription Undertakings by Transfer of Subscription Rights

January 28, 2014

One of NeuroVive's shareholders, Baulos Capital (formerly Private Placement Sprl) and Dr. Guo Weicheng, co-founder of Sihuan Pharmaceuticals (the company's partner in China ) announced they have undertaken to subscribe for both their participating interests in NeuroVive's current right share issue. According to a release, additionally, Maas Biolab, NeuroVive's shareholder, has undertaken to donate for free and transfer a total of approx. 2 million subscription rights to Baulos Capital and Dr. Guo Weicheng, which Baulos Capital and Dr. Guo Weicheng have undertaken to subscribe for. Overall, this means a commitment by Baulos Capital to subscribe for 595,000 shares, or approx. SEK 8.3 m, and by Dr. Guo Weicheng a commitment to subscribe for 358,250 shares, or approx. SEK 5 m in the rights share issue. The subscription period for NeuroVive's current rights share issue continues until 27 January 2014 and is open to current and new investors and shareholders. NeuroVive Pharmaceutical AB (publ) is a mitochondrial medicine company. More Information: ((Comments on this story may be sent to ))

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Manufacturing Close - Up

Story Tools